The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure
Ruben Hernaez,Constantine J. Karvellas,Yan Liu,Sophie-Caroline Sacleux,Saro Khemichian,Lance L. Stein,Kirti Shetty,Christina C. Lindenmeyer,Justin R. Boike,Douglas A. Simonetto,Robert S. Rahimi,Prasun K. Jalal,Manhal Izzy,Michael S. Kriss,Gene Y. Im,Ming V. Lin,Janice H. Jou,Brett E. Fortune,George Cholankeril,Alexander Kuo,Nadim Mahmud,Fasiha Kanwal,Faouzi Saliba,Vinay Sundaram,Thierry Artzner,Rajiv Jalan,Atef Al Attar,Kambiz Kosari,Richard Garcia,Gevork Salmastyan,William Cranford,Preet Patel,Pei Xue,Soumya Mishra,Madison Parks,Gianina Flocco,Jing Gao,Tiffany Wu,Priya Thanneeru,Vikrant Reddy,Jing Gao,Mariana Hurtado,Islam Mohamed,Ross Vyhmeister,Christine R. Lopez,Braidie Campbell,Adam C. Winters,Mary Ann Simpson,Xiaohan Ying
DOI: https://doi.org/10.1016/j.jhep.2023.05.028
IF: 25.7
2023-06-01
Journal of Hepatology
Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS">Twenty-eight-day mortality ranges from 30-90% in patients with acute-on-chronic liver failure grades 2/3 (severe ACLF). Though liver transplantation (LT) has demonstrated a survival benefit, the scarcity of donor organs and uncertainty regarding post-LT mortality among patients with severe ACLF may cause hesitancy. We developed and externally validated a model to predict 1-year post-LT mortality in severe ACLF, called the Sundaram ACLF-LT-Mortality (SALT-M) score, and estimated the median length of stay (LoS) after LT (ACLF-LT-LoS).</AbstractText>METHODS: <AbstractText Label="METHODS">In 15 LT centers in the US, we retrospectively identified a cohort of patients with severe ACLF transplanted between 2014-2019, followed up to Jan'2022. Candidate predictors included demographics, clinical and laboratory values, and organ failures. We selected predictors in the final model using clinical criteria and externally validated them in two French cohorts. We provided measures of overall performance, discrimination, and calibration. We used multivariable median regression to estimate LoS after adjusting for clinically relevant factors.</AbstractText>RESULTS: <AbstractText Label="RESULTS">We included 735 patients, of whom 521 (70.8%) had severe ACLF (120 ACLF-3, external cohort). The median age was 55 years, and 104 with severe ACLF (19.9%) died within 1-year post-LT. Our final model included age &gt;50 years, use of 1/≥2 inotropes, presence of respiratory failure, diabetes mellitus, and BMI (continuous). The c-statistic was 0.72 (derivation) and 0.80 (validation), indicating adequate discrimination and calibration based on the observed/expected probability plots. Age, respiratory failure, BMI, and presence of infection independently predicted median LoS.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">The SALT-M score predicts mortality within 1-year after LT in patients with ACLF. The ACLF-LT-LoS score predicted median post-LT stay. Future studies using these scores could assist in determining transplant benefits.</AbstractText>IMPACT AND IMPLICATIONS: <AbstractText Label="IMPACT AND IMPLICATIONS">Liver transplantation (LT) may be the only life-saving procedure available to patients with acute-on-chronic liver failure (ACLF), but clinically instability can augment the perceived risk of post-transplant mortality at 1 year. We developed a parsimonious score with clinically and readily available parameters to objectively assess 1-year post-LT survival and predict median length of stay after LT. We developed and externally validated a clinical model called the Sundaram ACLF-LT-Mortality score in 521 US patients with ACLF with 2 or ≥3 organ failure(s) and 120 French patients with ACLF grade 3. The c-statistic was 0.72 in the development cohort and 0.80 in the validation cohort. We also provided an estimation of the median length of stay after LT in these patients. Our models can be used in discussions on the risks/benefits of LT in patients listed with severe ACLF. Nevertheless, the score is far from perfect and other factors, such as patient's preference and center-specific factors, need to be considered when using these tools.</AbstractText>
gastroenterology & hepatology